Fundraising Fox

Aventera Antibodies

Lund, SE · 1 known investors

Aventera Antibodies is a preclinical biotech developing a first-in-class precision immunotherapy — an engineered monoclonal antibody — against invasive Group A Streptococcal (iGAS) infections, with first-in-human trials planned for 2028. The therapy is intended to be paired with rapid Strep-A diagnostics to enable early clinical intervention.

BiotechDeep TechHealthtech

Founders & leadership

AI
Arman IzadiinCEO & Founder
PN
Pontus NordenfeltinChairman of the Scientific Advisory Board, Board of Directors, Founder
CG
Caitriona GrönberginHead of Preclinical
LW
Lena Wester RosenlöfinHead of CMC

Investors · 1

LU InnovationLund

Frequently asked questions

What does Aventera Antibodies do?
Aventera Antibodies is a preclinical biotech developing a first-in-class precision immunotherapy — an engineered monoclonal antibody — against invasive Group A Streptococcal (iGAS) infections, with first-in-human trials planned for 2028. The therapy is intended to be paired with rapid Strep-A diagnostics to enable early clinical intervention.
Who founded Aventera Antibodies?
Aventera Antibodies was founded by Arman Izadi, Pontus Nordenfelt.
Who are Aventera Antibodies's investors?
Aventera Antibodies's investors include LU Innovation.
Where is Aventera Antibodies headquartered?
Aventera Antibodies is headquartered in Lund, SE.